Braveheart Bio Earnings Call Transcripts
Fiscal Year 2026
-
The 52-week oHCM extension showed early gradient responses and sustained improvements in exercise capacity, symptoms and disease markers, with encouraging safety. Phase III programs span both HCM forms; fixed-dose TRUEHEART-HCM is planned to start in H1 2027.
-
The forum highlighted strong clinical progress in HCM, with BHB-1893 showing rapid, deep efficacy and a differentiated safety profile. Simplified dosing, positive regulatory feedback, and robust financials position the program for global phase III advancement and potential early filing.
-
Lead asset BHB-1893 has shown promising phase II results in both obstructive and non-obstructive HCM, with significant biomarker and structural improvements. Global phase III trials are underway, aiming for simplified dosing and broader market adoption, supported by a robust regulatory and financial strategy.